We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

61 hedge funds and large institutions have $85.6M invested in Cartesian Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

47% more capital invested

Capital invested by funds: $58.3M → $85.6M (+$27.3M)

16.7% more ownership

Funds ownership: 1.13% → 17.82% (+17%)

12% less funds holding

Funds holding: 69 → 61 (-8)

26% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 27

Holders
61
Holders Change
-8
Holders Change %
-11.59%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
25
Reduced
10
Closed
27
Calls
$114K
Puts
–
Net Calls
+$114K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$6.2M
2
JP Morgan Chase
JP Morgan Chase
New York
+$6.18M
3
IC
Ikarian Capital
Texas
+$5.78M
4
BlackRock
BlackRock
New York
+$3.96M
5
LGM
Logos Global Management
California
+$2.15M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$23M
2
Millennium Management
Millennium Management
New York
-$647K
3
CM
CM Management
Florida
-$199K
4
Invesco
Invesco
Georgia
-$159K
5
Jane Street
Jane Street
New York
-$124K
Name Holding Trade Value Shares
Change 		Change in
Stake
WWP
51
WR Wealth Planners
Missouri
$1.05K -$24 -1 -3%
National Bank of Canada
52
National Bank of Canada
Quebec, Canada
$970 +$955 +40 New
Mirae Asset Global Investments
53
Mirae Asset Global Investments
South Korea
$669 +$88.7K +3,715 New
FFA
54
Farther Finance Advisors
California
$436 – – –
Nisa Investment Advisors
55
Nisa Investment Advisors
Missouri
$378 +$334 +14 New
AAP
56
Arax Advisory Partners
Colorado
$325 +$286 +12 New
PA
57
Parallel Advisors
California
$81 – – –
Goldman Sachs
58
Goldman Sachs
New York
– -$23M -39,335 Closed
Millennium Management
59
Millennium Management
New York
– -$647K -33,154 Closed
CM
60
CM Management
Florida
– -$199K -10,183 Closed
Invesco
61
Invesco
Georgia
– -$159K -8,157 Closed
Jane Street
62
Jane Street
New York
– -$124K -6,340 Closed
IIM
63
Ironwood Investment Management
Massachusetts
– -$115K -5,894 Closed
Squarepoint
64
Squarepoint
New York
– -$70.6K -3,623 Closed
Citadel Advisors
65
Citadel Advisors
Florida
– -$64.7K -3,318 Closed
AIG
66
American International Group
New York
– -$36.5K -1,873 Closed
SG Americas Securities
67
SG Americas Securities
New York
– -$31K -1,571 Closed
VOYA Investment Management
68
VOYA Investment Management
Georgia
– -$29.9K -1,533 Closed
Susquehanna International Group
69
Susquehanna International Group
Pennsylvania
– -$29.3K -1,505 Closed
Prudential Financial
70
Prudential Financial
New Jersey
– -$27.6K -1,417 Closed
AF
71
Alerus Financial
North Dakota
– -$19.5K -1,000 Closed
BAM
72
Belpointe Asset Management
Nevada
– -$18.5K -947 Closed
Dimensional Fund Advisors
73
Dimensional Fund Advisors
Texas
– -$15.7K -804 Closed
ProShare Advisors
74
ProShare Advisors
Maryland
– -$13.3K -683 Closed
AllianceBernstein
75
AllianceBernstein
Tennessee
– -$11.2K -576 Closed
1 2
3
4

RNAC Hedge Fund Activity: Q2 2024 in Review

61 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2024, worth a combined $85.6M — up 47% from $58.3M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RNAC and 20 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 25 added.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $6.2M. The largest seller was Goldman Sachs, exiting entirely with an estimated $23M sold.

  • 61 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2024, down from 69 in Q1 2024.
  • Funds reported $85.6M of Cartesian Therapeutics stock for Q2 2024, up 47% quarter-over-quarter.
  • 20 funds opened new Cartesian Therapeutics positions in Q2 2024 and 27 closed out, a net change of -7 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2024 was MPM BioImpact, an estimated $6.2M added.
  • The largest Cartesian Therapeutics seller in Q2 2024 was Goldman Sachs, an estimated $23M sold.

Based on aggregated 13F filings for Q2 2024.